Wells Fargo initiated coverage of Heartflow (HTFL) with an Overweight rating and $38 price target The firm sees upside to Street estimates from he company’s fractional flow reserve-computed tomography and plaque volumes. Heartflow has a “strong first mover advantage” in software and AI-based diagnosis and management of coronary artery disease, a leading cause of death, the analyst tells investors in a research note. Wells sees the company as a 20% grower the next three years driven by its FFRCT and plaque analyses.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HTFL:
- HeartFlow updates investors, emphasizing AI coronary diagnostics
- Heartflow announces Plaque Analysis covered by Aetna insurance plans
- Twelve new option listings and two option delistings on December 24th
- Insiders Step in on These 2 ‘Strong Buy’ Stocks — And Analysts Are on the Same Page
- ACC, AHA publish scientific statements supporting Heartflow plaque analysis